Cargando…
729. Comparing Length of Stay and Clinical Outcomes for Hospitalized Patients at Bridgeport Hospital who Received Baloxavir Marboxil (BM) or Oseltamivir Phosphate (OP) During the 2018–2019 Influenza Season
BACKGROUND: BM has been approved for the management of acute uncomplicated influenza in otherwise healthy individuals between age 12 and 64, and found to have a greater reduction in viremia. The original trial excluded hospitalized patients and those with co-morbidities. METHODS: This is a single-ce...
Autores principales: | Nachiappan, Arun C, Yang, Wei-Teng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811280/ http://dx.doi.org/10.1093/ofid/ofz360.797 |
Ejemplares similares
-
922. Cost-effectiveness of baloxavir marboxil versus oseltamivir or no treatment for the management of influenza in the United States
por: Hansen, Svenn, et al.
Publicado: (2023) -
1518. Real-World Comparative Effectiveness of Baloxavir Marboxil versus Oseltamivir on Influenza-Related Complication and Resource Utilization
por: Neuberger, Eddie, et al.
Publicado: (2020) -
Early Fever Resolution in Early Childhood Influenza Treated with Baloxavir Marboxil: A Retrospective Study Compared to Those with Oseltamivir
por: Nezu, Keiko, et al.
Publicado: (2023) -
Efficacy of baloxavir marboxil on household transmission of influenza infection
por: Umemura, Takumi, et al.
Publicado: (2020) -
Baloxavir Marboxil: An Original New Drug against Influenza
por: Dufrasne, François
Publicado: (2021)